Clinical Trials Logo

Clinical Trial Summary

The NAFLD Database 2 will recruit at least 1,500 new adult participants suspected or known to have NAFLD or nonalcoholic steatohepatitis (NASH)-related cirrhosis and will also invite adult participants from the prior NAFLD Database and related studies (PIVENS trial and TONIC trial) to enroll in the NAFLD Database 2. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications.


Clinical Trial Description

To add to the existing NAFLD Database an additional 1,500 adult participants with a diagnosis of NAFLD, supported by a recent liver biopsy, with a broad range of severity. Core data collection will include clinical, demographic, laboratory, imaging, and histological features - To increase the population diversity of the NAFLD Database to provide greater representation of Hispanic, Native American, African American, and Asian patients among the new adult participants recruited into the NAFLD Database 2 - To expand the current specimen bank comprised of liver tissue, serum, plasma, and DNA obtained from new participants and continuing participants undergoing repeat liver biopsy with the specific goal of optimizing the collection of plasma or serum suitable for biomarker development studies by obtaining specimens in close temporal proximity to the performance of liver biopsy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01030484
Study type Observational
Source Johns Hopkins Bloomberg School of Public Health
Contact
Status Completed
Phase
Start date December 2, 2009
Completion date May 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT01968395 - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Phase 4
Completed NCT01437969 - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting NCT00155376 - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Phase 4
Recruiting NCT00172705 - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique N/A
Completed NCT04185454 - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese N/A
Completed NCT02506335 - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease Early Phase 1
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed NCT02306018 - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation N/A
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed NCT01970904 - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients N/A
Terminated NCT00741117 - Conjugated Hyperbilirubinemia and Pulse Oximetry N/A
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00245830 - Ischemic Preconditioning of Liver in Cadaver Donors N/A
Completed NCT00074386 - Kidney and Liver Transplantation in People With HIV N/A
Completed NCT02329821 - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection N/A
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Completed NCT01650181 - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Phase 4
Completed NCT00799851 - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices Phase 4
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3